Document Detail


Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin.
MedLine Citation:
PMID:  10341841     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Many of the acute coronary ischemic syndromes are triggered by spontaneous or mechanical disruption of atherosclerotic plaques with resultant activation of platelets and coagulation. Given the central role of platelets and thrombin in arterial thrombosis, current strategies for its prevention and treatment focus on both inhibition of platelet aggregation and control of thrombin generation and activity. Although aspirin and unfractionated heparin are the cornerstones of current treatment strategies, both have limitations. This review will describe these limitations and discuss new antithrombotic agents developed for use in acute coronary ischemic syndromes and as adjuncts for percutaneous coronary revascularization procedures.
Authors:
S M Bates; J I Weitz
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Cardiovascular research     Volume:  41     ISSN:  0008-6363     ISO Abbreviation:  Cardiovasc. Res.     Publication Date:  1999 Feb 
Date Detail:
Created Date:  1999-06-07     Completed Date:  1999-06-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0077427     Medline TA:  Cardiovasc Res     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  418-32     Citation Subset:  IM    
Affiliation:
McMaster University, Hamilton, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / therapeutic use*
Aspirin / therapeutic use
Fibrinolytic Agents / therapeutic use
Heparin / therapeutic use
Humans
Myocardial Ischemia / drug therapy*
Platelet Aggregation Inhibitors / therapeutic use
Thrombin / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 9005-49-6/Heparin; EC 3.4.21.5/Thrombin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Strategies to achieve coronary arterial plaque stabilization.
Next Document:  Stents covered by an autologous arterial graft in porcine coronary arteries: feasibility, vascular i...